Literature DB >> 28843863

Administration of riluzole to the basolateral amygdala facilitates fear extinction in rats.

Azusa Sugiyama1, Misa Yamada2, Akiyoshi Saitoh2, Jun-Ichiro Oka3, Mitsuhiko Yamada4.   

Abstract

A general understanding exists that inhibition of glutamatergic neurotransmission in the basolateral amygdala (BLA) impairs fear extinction in rodents. Surprisingly, we recently found that systemic administration of riluzole, which has been shown to inhibit the glutamatergic system, facilitates extinction learning in rats with a preconditioned contextual fear response. However, the mechanisms underlying this paradoxical effect of riluzole remain unclear. In this study, adult male Wistar rats were bilaterally cannulated in the BLA to examine the effects of intra-BLA administration of riluzole. We also compared the effects of riluzole with those of d-cycloserine, a partial agonist at the glycine-binding region of the N-methyl-d-aspartate (NMDA) receptor. In this study, intra-BLA administration of either riluzole or d-cycloserine facilitated extinction learning of contextual fear in conditioned rats. In addition, both riluzole and d-cycloserine enhanced the acquisition of recognition memory in the same model. However, intra-BLA injections of riluzole, but not d-cycloserine, had a potent anxiolytic-like effect when investigated using an elevated plus-maze test. Our findings suggest that riluzole-induced facilitation of extinction learning in rats with a preconditioned contextual fear reflects an indirect effect, resulting from the intra-BLA administration of the drug, and might not be directly related to inhibition of glutamatergic signaling. Further research is needed to clarify the mechanisms underlying the paradoxical effect of riluzole on fear extinction learning observed in this study.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; Basolateral amygdala; Fear conditioning; Recognition memory; Riluzole; d-Cycloserine

Mesh:

Substances:

Year:  2017        PMID: 28843863     DOI: 10.1016/j.bbr.2017.08.031

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  4 in total

1.  Administration of a delta opioid receptor agonist KNT-127 to the basolateral amygdala has robust anxiolytic-like effects in rats.

Authors:  Azusa Sugiyama; Misa Yamada; Akiyoshi Saitoh; Hiroshi Nagase; Jun-Ichiro Oka; Mitsuhiko Yamada
Journal:  Psychopharmacology (Berl)       Date:  2018-07-31       Impact factor: 4.530

2.  Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.

Authors:  Patricia T Spangler; James C West; Catherine L Dempsey; Kyle Possemato; Danielle Bartolanzo; Pablo Aliaga; Carlos Zarate; Meena Vythilingam; David M Benedek
Journal:  J Clin Psychiatry       Date:  2020-10-27       Impact factor: 4.384

Review 3.  Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.

Authors:  A Irem Sonmez; Ammar Almorsy; Laura B Ramsey; Jeffrey R Strawn; Paul E Croarkin
Journal:  Depress Anxiety       Date:  2020-05-17       Impact factor: 6.505

Review 4.  Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits.

Authors:  Manoranjan S D'Souza
Journal:  Front Psychiatry       Date:  2019-07-24       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.